Matrisys Bioscience News Today

The report by Orbisresearch.com on the global Living Biological Drugs market provides a thorough analysis of several factors, such as major vendors an

Global Microbiome Therapeutics and Diagnostics Market

/PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic...

/PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic...

Netherton Syndrome Market research report 2022 offers country analysis, competitive landscape, industry overview and challenges of the industry has been analysed in the report.

Arthrosi Expands Disease Expertise with New Board of Director Appointment News provided by Share this article Share this article SAN DIEGO, April 20, 2021 /PRNewswire/ -- Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors. Dr. Mackay brings more than 30 years of in-depth experience to the team, as they reach Phase2b in the clinical development of AR882, the next generation molecule for the treatment of gout. "We are pleased to welcome D...

PharmiWeb.com is Europes leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2021.3.24.1 You are leaving PharmiWeb.com Disclaime...

email article A topical atopic dermatitis (AD) treatment derived from skin bacteria demonstrated safety and preliminary evidence of clinical activity in a proof-of-principle study. After seven days of treatment, MSB-0221 significantly reduced Staphylococcus aureus colonization in S. aureus toxin PSM-alpha. The compound inhibited inflammation-inducing toxin irrespective of its activity against S. aureus. A post hoc evaluation limited to patients with confirmed S. aureus killing suggest...

Share: Industry Experts Provide Added Depth to Board of Directors and Advisory Board TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board. Philippe Calais, Pharm D, Ph.D., President, Chief Executive Officer and a director of MatriSys Bioscience, Inc., has been elected Chairman of the Board of Directors of TransCode. Dr. Calais has served on ...